Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DXCM

DXCM - DexCom Inc Stock Price, Fair Value and News

$73.37-0.30 (-0.41%)
Market Closed

60/100

DXCM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

60/100

DXCM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$75.92

Target 3M

$73.59

Target 6M

$74.39

DXCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DXCM Price Action

Last 7 days

1.8%

Last 30 days

8.7%

Last 90 days

7.6%

Trailing 12 Months

-17.0%

DXCM RSI Chart

DXCM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DXCM Valuation

Market Cap

28.6B

Price/Earnings (Trailing)

39.71

Price/Sales (Trailing)

6.34

EV/EBITDA

22.25

Price/Free Cashflow

26.95

DXCM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$75.92

Target 3M

$73.59

Target 6M

$74.39

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

4.5B

Rev. Growth (Yr)

21.64%

Rev. Growth (Qtr)

4.51%

DXCM Earnings

Earnings (TTM)

720.7M

Earnings Growth (Yr)

110.85%

Earnings Growth (Qtr)

57.84%

DXCM Profitability

Operating Margin

95.68%

EBT Margin

21.24%

Return on Equity

26.44%

Return on Assets

9.61%

Free Cashflow Yield

3.71%

DXCM Investor Care

Buy Backs (1Y)

0.15%

Diluted EPS (TTM)

1.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.1B4.3B4.5B0
20243.8B3.9B4.0B4.0B
20233.0B3.2B3.4B3.6B
20222.6B2.7B2.8B2.9B
20212.0B2.2B2.3B2.4B
20201.6B1.7B1.8B1.9B
20191.1B1.2B1.4B1.5B
2018760.6M832.5M914.6M1.0B
2017599.4M632.7M668.7M718.5M
2016445.4M489.8M534.2M573.3M
2015285.1M319.2M354.4M402.0M
2014177.1M200.1M226.2M259.0M
2013109.5M121.8M141.6M160.0M
201282.2M84.3M89.1M100.0M
201153.3M62.9M69.5M76.3M
201000048.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About DexCom Inc

DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
 CEO
 WEBSITEdexcom.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES7500

DexCom Inc Frequently Asked Questions

DXCM is the stock ticker symbol of DexCom Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of DexCom Inc is 28.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DXCM's fair value in chart for subscribers.

The fair value guage provides a quick view whether DXCM is over valued or under valued. Whether DexCom Inc is cheap or expensive depends on the assumptions which impact DexCom Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DXCM.

As of Wed Jan 28 2026, DXCM's PE ratio (Price to Earnings) is 39.71 and Price to Sales (PS) ratio is 6.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DXCM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, DexCom Inc has provided 0.152 (multiply by 100 for percentage) rate of return.